CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 63 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $1,000 | -97.7% | 92 | -98.3% | 0.00% | -100.0% |
| Q1 2021 | $43,000 | +65.4% | 5,515 | +74.6% | 0.00% | 0.0% |
| Q2 2020 | $26,000 | -56.7% | 3,158 | -60.2% | 0.00% | -60.0% |
| Q1 2020 | $60,000 | +114.3% | 7,941 | +133.2% | 0.01% | +150.0% |
| Q4 2019 | $28,000 | +75.0% | 3,405 | +137.9% | 0.00% | +100.0% |
| Q2 2019 | $16,000 | +300.0% | 1,431 | +255.1% | 0.00% | – |
| Q1 2019 | $4,000 | -88.2% | 403 | -77.2% | 0.00% | -100.0% |
| Q3 2018 | $34,000 | -99.9% | 1,764 | -27.5% | 0.00% | -40.0% |
| Q2 2018 | $55,619,000 | +126306.8% | 2,433 | +59.9% | 0.01% | +25.0% |
| Q1 2018 | $44,000 | +175.0% | 1,522 | +104.8% | 0.00% | +300.0% |
| Q4 2017 | $16,000 | +23.1% | 743 | +4.5% | 0.00% | 0.0% |
| Q3 2017 | $13,000 | +225.0% | 711 | +155.8% | 0.00% | – |
| Q2 2017 | $4,000 | -20.0% | 278 | 0.0% | 0.00% | – |
| Q1 2017 | $5,000 | -16.7% | 278 | -48.6% | 0.00% | -100.0% |
| Q4 2016 | $6,000 | – | 541 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 5,576,471 | $36,526,000 | 1.44% |
| Altium Capital Management LP | 273,703 | $1,793,000 | 0.67% |
| Jackson Creek Investment Advisors LLC | 80,367 | $526,000 | 0.21% |
| HARBOURVEST PARTNERS LLC | 79,193 | $519,000 | 0.20% |
| XTX MARKETS LLC | 14,169 | $93,000 | 0.19% |
| Perceptive Advisors | 2,577,043 | $16,880,000 | 0.18% |
| RTW INVESTMENTS, LP | 1,527,352 | $10,004,000 | 0.17% |
| Exane Asset Management | 30,568 | $200,220,000 | 0.14% |
| Virtus ETF Advisers LLC | 37,343 | $245,000 | 0.10% |
| Congress Park Capital LLC | 25,807 | $169,000 | 0.10% |